Table 1. Five-year overall survival (OS) and disease-free survival (DFS) probabilities based on Kaplan-Meier in sentinel node staged patients with CM (n = 1909).

Prognostic Factor	Number of Patients n (%)	Censored (%) at OS	P value 5-year OS [95% CI]	Censored (%) at DFS	P-value 5-year DFS [95% CI]
Thickness			P<0.0001		P<0.001
≤1.00 mm	188 (9.8%)	96.8	97.5 [94.6, 100]	94.1	96.9 [94.2, 99.6]
1.01–2.00 mm	934 (48.9%)	93.9	93.0 [90.7, 95.3]	86.6	84.2 [81.3, ,87.1]
2.01–4.00 mm	565 (29.6%)	86.2	82.8 [78.7, 86.9]	71.9	64.2 [59.7, 68.7]
>4 mm	222 (11.6%)	77.9	68.3 [60.1, 76.5]	61.7	55.3 [47.1, 63.5]
Ulceration			P<0.0001		P<0.001
absent	1094 (68.2%)	93.3	93.2 [91.3, 95.1]	87.3	86.2 [83.9, 88.5]
present	511 (31.8%)	83.0	75.8 [70.9, 80.7]	66.9	57.7 [52.5, 62.9]
Body site			P<0.0001		P<0.001
Head and Neck	231 (12.1%)	91.3	88.7 [83.0, 94.4]	79.1	75.5 [68.5, 82.6]
Trunk	729 (38.2%)	87.0	84.3 [81.0, 87.6]	78.1	74.1 [66.3, 78.0]
Upper limb	343 (18.0%)	97.1	95.6 [92.7, 98.5]	91.3	89.2 [85.1, 93.3]
Lower limb	606 (31.7%)	89.3	88.7 [85.6, 91.8]	76.4	72.6 [68.5, 76.7]
AJCC Stage			p<0.001		p<0.001
I A	90 (5.3%)	100.0	100.0	95.2	97.2 [95.2, 99.2]
I B	824 (43.2%)	96.0	96.2 [94.4, 98.0]	90.9	90.3 [89.0, 91.6]
II A	434 (22.7%)	90.6	87.0 [82.9, 91.1]	80.6	75.4 [72.9, 77.9]
II B	260 (13.6%)	83.8	78.1 [71.2, 85.0]	67.7	58.2 [54.2, 62.2]
II C	87 (4.6%)	80.5	72.6 [59.5, 83.9]	59.8	50.7 [43.0, 58.4]
III A	119 (6.2%)	73.1	72.6 [62.8, 82.4]	53.8	45.9 [40.4, 51.4]
III B	95 (5.0%)	73.7	65.6 [53.4, 77.8]	54.7	44.9 [38.7, 51.1]
Age			P = 0.035		P = 0.001
< = 45-year	531 (27.8%)	92.1	92.0 [89.3, 94.7]	84.0	82.6 [78.9, 86.3]
46–60 years	529 (27.7%)	87.7	86.3 [82.8, 89.8]	78.8	76.8 [72.7, 80.9]
61–70 years	454 (23.8%)	88.1	85.0 [80.7, 89.3]	78.0	73.7 [68.8, 78.6]
>70 years	395 (20.7%)	92.7	88.0 [83.1, 92.9]	79.0	70.2 [64.1, 76.3]
Gender			P = 0.068		P = 0.135
Male	1012 (53.0%)	88.8	86.2 [79.6, 93.0]	78.8	74.6 [74.5, 77.9]
Female	897(47.0%)	91.4	89.5 [87.0, 92.0]	81.6	78.0 [74.7, 81.3]
Clark-Level			P<0.0001		P<0.001
Level II	12 (0.7%)	100.0	100.0	91.7	85.7 [80.7, 88.2]
Level III	209 (12.6%)	95.7	93.1 [91.0, 95.1]	89.0	88.2 [83.3, 93.1]
Level IV	1350 (81.4%)	90.8	89.1 [88.0, 90.2]	80.6	76.9 [76.8, 79.6]
Level V	88 (5.3%)	75.0	82.3 [79.1, 85.5]	60.2	55.1 [43.0, 67.2]
Histological Subtype			P<0.001		P<0.001
SSM	993 (54.6%)	90.2	91.0 [89.9, 92.1]	82.6	80.6 [79.5, 81.7]
NM	437(24.0%)	86.2	82.9 [79.7, 82.3]	74.8	69.1 [66.4, 71.8]
LMM	81 (4.5%)	96.3	95.2 [69.5, 79.1]	88.9	86.2 [81.4, 91.0]
ALM	150 (8.2%)	81.3	74.3 [92.5, 97.9]	65.3	56.2 [51.2, 61.7]
Other	158 (8.7%)	95.6	93.2 [87.9, 98.5]	89.2	83.8 [76.2, 91.4]
SLNB status			P<0.001		P<0.001
negative	1697 (88.9%)	92.0	90.3 [88.5, 92.1]	83.3	80.6 [78.2, 83.0]
positive	212 (11.1%)	74.5	70.9 [63.3, 78.5]	54.2	46.0 [38.0, 54.1]

SD = Standard Deviation; IQR = Inter-Quartile Range; SSM = superficial spreading melanoma, NM = nodular melanoma, LMM = lentigious malignant melanoma, ALM = Acral lentigious melanoma; AJCC = American Joint Committee of Cancer.